CapsoVision (CV) vs TransMedics Group (TMDX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
CapsoVision (CV) has outperformed TransMedics Group (TMDX) over the past year, gaining 16.8% versus a loss of 34.9%. TransMedics Group is the larger company by market cap ($2.96 billion vs $327.6 million), about 9.0 times the size. TransMedics Group converts more of its revenue into profit, with a net margin of 31.4% versus -186.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CV | TMDX |
|---|---|---|
| Share price | $6.11 | $85.25 |
| Market cap | $327.56M | $2.96B |
| 1-day change | -3.17% | -9.33% |
| YTD return | -42.84% | -29.92% |
| 1-year return | +16.83% | -34.89% |
| 5-year return | — | +289.09% |
| P/E ratio (TTM) | — | 23.23 |
| Forward P/E | — | 34.31 |
| EPS (TTM) | $-0.42 | $3.67 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $13.55M | $605.49M |
| Revenue growth (YoY) | +15.29% | +37.13% |
| Net income (latest FY) | $-25.32M | $190.29M |
| Gross margin | 52.92% | 59.92% |
| Operating margin | -188.25% | 17.93% |
| Net margin | -186.77% | 31.43% |
| 52-week high | $15.37 | $156.00 |
| 52-week low | $4.50 | $60.11 |
| Distance from 52-week high | -60.25% | -45.35% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +55.48% | +23.70% |
| Average volume | 173.59K | 930.13K |
| Shares outstanding | 53.61M | 34.73M |
| Employees | 99 | 898 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TransMedics Group is about 9.0 times larger than CapsoVision by market value ($2.96B vs $327.56M).
- CV has outperformed TMDX by 51.7 percentage points over the past year.
- TransMedics Group is more profitable, keeping 31.4 cents of every revenue dollar as net income versus -186.8 cents for CapsoVision.
- TransMedics Group grew revenue faster in its latest fiscal year (+37.13% vs +15.29%).
About CapsoVision
CV stock →CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon).
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 99 employees
About TransMedics Group
TMDX stock →TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 898 employees
CV vs TMDX FAQ
Which is bigger, CapsoVision or TransMedics Group?
TransMedics Group (TMDX) is larger, with a market capitalization of $2.96B compared with $327.56M for CapsoVision (CV).
Which stock has performed better over the past year, CV or TMDX?
CV returned +16.83% over the past 12 months, compared with -34.89% for TMDX (price return, excluding dividends). Past performance does not predict future results.
Are CapsoVision and TransMedics Group in the same industry?
Yes. Both are classified in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry within the Health Care sector.